The neurocognitive effects of extended-release methylphenidate in healthy adults: a review and placebo-controlled randomised controlled trial

Methylphenidate is increasingly used off-label by healthy adults seeking cognitive enhancement despite limited evidence supporting its efficacy outside attention-deficit/hyperactivity disorder (ADHD). Most studies in healthy populations employ acute, single-dose designs and report inconsistent findings across cognitive domains. This study aimed to evaluate the effects of prescription stimulants on cognition in healthy adults and to determine whether sustained administration of extended-release methylphenidate confers neurocognitive benefits beyond placebo. A two-part study was conducted. First, a systematic review examined placebo-controlled studies evaluating prescription stimulants and objective neurocognitive performance in healthy adults. Second, a randomised, double-blind, placebo-controlled crossover trial was performed in 28 healthy, drug-naïve adults (25 females, 3 males; mean age 30.2 ± 10.8 years). Participants received extended-release methylphenidate (20 mg/day) and placebo for 14 days each, separated by a 48-hour washout period. Neurocognitive performance was assessed using the CNS Vital Signs ® battery at baseline and after each intervention period across six cognitive domains. The systematic review identified 10 eligible studies and demonstrated that prescription stimulants produce small, domain-specific improvements, most consistently in sustained attention, inhibitory control, and episodic memory. Meta-analytic evidence indicated only modest overall effects for methylphenidate (standardized mean difference approximately 0.21). In the clinical trial, executive function, cognitive flexibility, and reaction time improved significantly from baseline following both methylphenidate and placebo administration (all p < 0.05). However, no significant differences were observed between methylphenidate and placebo for any neurocognitive outcome (all p > 0.05), with negligible between-condition effect sizes (overall Cohen’s d = 0.17). Current evidence suggests that prescription stimulants produce only modest and domain-specific cognitive effects in healthy adults. In this randomised crossover trial, short-term administration of extended-release methylphenidate did not improve neurocognitive performance beyond placebo. The observed improvements appear more consistent with practice, expectancy, and task-familiarity effects than with sustained pharmacological enhancement. These findings challenge assumptions regarding the effectiveness of off-label stimulant use for cognitive enhancement in healthy individuals. Pan African Clinical Trials Registry (PACTR202011697726048 registered 11 November 2020) and ClinicalTrials.gov (NCT07742631 registered 28 July 2026).

Authors

Institutions

Publication Details

Journal
BMC Pharmacology and Toxicology
Published
2026-11-16
DOI
https://doi.org/10.1186/s40360-026-01272-3
Primary Topic
Neuroethics, Human Enhancement, Biomedical Innovations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The neurocognitive effects of extended-release methylphenidate in healthy adults: a review and placebo-controlled randomised controlled trial

Demitri Constantinou, Mike Lambert, Alan Rothberg
BMC Pharmacology and Toxicology
Neuroethics, Human Enhancement, Biomedical Innovations
article

The neurocognitive effects of extended-release methylphenidate in healthy adults: a review and placebo-controlled randomised controlled trial

Demitri Constantinou, Mike Lambert, Alan Rothberg
article en

Abstract

Methylphenidate is increasingly used off-label by healthy adults seeking cognitive enhancement despite limited evidence supporting its efficacy outside attention-deficit/hyperactivity disorder (ADHD). Most studies in healthy populations employ acute, single-dose designs and report inconsistent findings across cognitive domains. This study aimed to evaluate the effects of prescription stimulants on cognition in healthy adults and to determine whether sustained administration of extended-release methylphenidate confers neurocognitive benefits beyond placebo. A two-part study was conducted. First, a systematic review examined placebo-controlled studies evaluating prescription stimulants and objective neurocognitive performance in healthy adults. Second, a randomised, double-blind, placebo-controlled crossover trial was performed in 28 healthy, drug-naïve adults (25 females, 3 males; mean age 30.2 ± 10.8 years). Participants received extended-release methylphenidate (20 mg/day) and placebo for 14 days each, separated by a 48-hour washout period. Neurocognitive performance was assessed using the CNS Vital Signs ® battery at baseline and after each intervention period across six cognitive domains. The systematic review identified 10 eligible studies and demonstrated that prescription stimulants produce small, domain-specific improvements, most consistently in sustained attention, inhibitory control, and episodic memory. Meta-analytic evidence indicated only modest overall effects for methylphenidate (standardized mean difference approximately 0.21). In the clinical trial, executive function, cognitive flexibility, and reaction time improved significantly from baseline following both methylphenidate and placebo administration (all p < 0.05). However, no significant differences were observed between methylphenidate and placebo for any neurocognitive outcome (all p > 0.05), with negligible between-condition effect sizes (overall Cohen’s d = 0.17). Current evidence suggests that prescription stimulants produce only modest and domain-specific cognitive effects in healthy adults. In this randomised crossover trial, short-term administration of extended-release methylphenidate did not improve neurocognitive performance beyond placebo. The observed improvements appear more consistent with practice, expectancy, and task-familiarity effects than with sustained pharmacological enhancement. These findings challenge assumptions regarding the effectiveness of off-label stimulant use for cognitive enhancement in healthy individuals. Pan African Clinical Trials Registry (PACTR202011697726048 registered 11 November 2020) and ClinicalTrials.gov (NCT07742631 registered 28 July 2026).

BMC Pharmacology and Toxicology
University of Cape Town (ZA), University of the Witwatersrand (ZA), Rhodes University (ZA)
Good health and well-being
Neuroethics, Human Enhancement, Biomedical Innovations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon